Page last updated: 2024-09-03

nifekalant hydrochloride and Tachycardia, Supraventricular

nifekalant hydrochloride has been researched along with Tachycardia, Supraventricular in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bao, H; Chen, Q; Cheng, X; Fan, S; Hong, K; Hu, J; Huang, L; Huang, Q; Ju, Z; Li, J; Marian, AJ; Wu, Y; Xia, Z; Xiong, Q; You, C; Yu, J; Yuan, P; Zhu, B1

Other Studies

1 other study(ies) available for nifekalant hydrochloride and Tachycardia, Supraventricular

ArticleYear
Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.
    Journal of the American Heart Association, 2019, 07-02, Volume: 8, Issue:13

    Topics: Accessory Atrioventricular Bundle; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Pyrimidinones; Tachycardia, Supraventricular; Ventricular Dysfunction, Left; Wolff-Parkinson-White Syndrome

2019